Pfizer today said it will delay applying for Emergency Use Authorization (EUA) of its COVID vaccine for infants and children 6 months to 4 years old stating there’s not enough data on the efficiency of a third dose.

The U.S. Food and Drug Administration (FDA) in response postponed a meeting that had been scheduled for Feb. 15 to review Pfizer’s application for the pediatric vaccine….

Continue reading >>>>